ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck & Co. has received FDA approval for the protease inhibitor boceprevir to be used in combination with PEGylated interferon and ribavirin for treating hepatitis C virus (HCV) infection. To be marketed as Victrelis, the drug is the first new HCV treatment in more than a decade. Just days after getting the regulatory nod, Merck signed a nonexclusive pact with Roche, under which the Swiss company will promote Victrelis alongside Pegasys, a PEGylated interferon. The deal is expected to give Merck a leg up on Vertex Pharmaceuticals, which is poised to win approval for its own HCV treatment, telaprevir. Merck and Roche will also work together to explore novel combinations of HCV drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter